Use of Real-World Data (RWD) and Real-World Evidence (RWE)

Rare diseases present unique challenges in drug development, including limited patient populations, poorly characterized natural histories, and a lack of validated endpoints. To address these challenges, regulatory agencies like the FDA have introduced flexibilities in evidence requirements and provided guidance specifically aimed at rare disease drug development. This paper reviews the regulatory landscape and challenges in rare disease drug development, highlighting the use of accelerated approval pathways and the importance of confirmatory trials. The FDA’s guidance outlines pathways for accelerated approval based on surrogate endpoints, along with the need for confirmatory evidence to demonstrate clinical benefit. Despite progress, over 10,000 rare diseases lack approved treatments, necessitating innovative approaches in drug development. Real-world data (RWD) from patient registries and natural history studies have emerged as valuable resources, aiding in clinical trial planning and endpoint modeling. However, challenges such as data bias and variability require careful consideration. Case examples, such as the approval of Lutathera for neuroendocrine tumors, demonstrate the utility of RWD in supporting regulatory decisions. Nonetheless, ensuring the quality and granularity of RWD remains crucial for unbiased evaluations. In conclusion, while RWD offers potential benefits in rare disease drug development, careful planning, methodological rigor, and collaboration among stakeholders are essential to harness its full potential and accelerate the development of effective treatments for rare diseases.